First test of WGc-043 injection for advanced EBV-related tumors
Part of Cancer clinical trials.
This trial tests a new injection called WGc-043 for people with advanced solid tumors that are linked to the Epstein-Barr virus. It aims to see if the treatment is safe and may help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced (locally recurrent or spread to other parts of the body) and positive for the Epstein-Barr virus (EBV).
- You should be able to do your daily activities with little to no help (ECOG 0-1).
- Your tumor must have at least one area that can be measured on a scan.
- You must be willing to use effective birth control if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA-based treatment for people with Epstein-Barr virus (EBV) related diseases, such as certain cancers or EBV illness after a transplant. The goal is to see if the treatment can help your immune system fight the virus and the disease.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This trial tests a new treatment, WGb-0301, for people with B-cell lymphoma or leukemia that has come back or not responded to other therapies. It aims to see if this therapy can help when standard options are no longer working.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests a new drug called GB268, which targets three different proteins (PD-1, CTLA-4, and VEGF) that help tumors grow and hide from the immune system. It is for people with advanced solid tumors who have tried standard treatments, or for whom no standard treatment is available.
This trial tests a combination of two experimental drugs, MHB088C and MHB039A, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Advanced EBV-positive Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.